The Top 5 Biosimilars Articles for the Week of November 26

The Center for Biosimilars® recaps the top news for the week of November 26, 2018.


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of November 26.

Number 5: Two new biosimilar pegfilgrastim products were authorized in the European Union this week, Ziextenzo and Pelmeg.

Number 4: The United Kingdom’s National Health Service announced that it completed negotiations this week over using the best-value adalimumab product. Under the new plan, it will save 300 million pounds of its current 400 million pounds per year spending on adalimumab.

Number 3: A newly proposed rule from CMS would allow plans to make broader use of prior authorization and step therapy for drugs— including drugs in protected classes­– that are covered under Medicare Part D.

Number 2: The European Commission, in conjunction with the Organization for Economic Co-operation and Development, released its annual Health at a Glance report which highlights the need for and value of generic and biosimilar products in Europe.

Number 1: The FDA approved Celltrion and Teva’s rituximab biosimilar this week, to be sold as Truxima.

Finally, last week, our e-newsletter asked if you agree that anti-biosimilar campaigns in the United States foster negative perceptions of biosimilars.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit